SAMANEH MOSTAFAVI, ZUHAIR MOHAMMAD HASSAN^*

Oncology Research, Vol.32, No.3, pp. 477-487, 2024, DOI:10.32604/or.2023.043926

Abstract Intracellular communications between breast cancer and fibroblast cells were reported to be involved in cancer proliferation, growth, and therapy resistance. The hallmarks of cancer-fibroblast interactions, consisting of caveolin 1 (Cav1) and mono-carboxylate transporter 4 (MCT4) (metabolic coupling markers), along with IL-6, TGFβ, and lactate secretion, are considered robust biomarkers predicting recurrence and metastasis. In order to promote a novel phenotype in normal fibroblasts, we predicted that breast cancer cells could be able to cause loss of Cav1 and increase of MCT4, as well as elevate IL-6 and TGFβ in nearby normal fibroblasts. We created a co-culture model using breast cancer… More >

ABDELAZIZ ADAM IDRISS ARBAB^1,3,#, CHUNQING YIN^4,#, XUBIN LU¹, YAN LIANG¹, ISMAIL MOHAMED ABDALLA¹, AMER ADAM IDRIS³, TIANLE XU^1,2, YONGJIANG MAO¹, ZHANGPING YANG^1,2,*

BIOCELL, Vol.46, No.11, pp. 2443-2454, 2022, DOI:10.32604/biocell.2022.020865

Abstract Mastitis is a common inflammatory cow mammary infection; that causes significant economic loss in dairy industry. Given the interesting connection between metformin’s anti-inflammatory function and mastitis model induced by LTA in pbMECs, our objective was to prove that metformin was beneficial in suppressing proinflammatory response induced by LTA through modulation of mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-κB) signaling pathways and activation of peroxisome proliferator-activated receptor-γ (PPARγ) in pbMECs. The proliferation of cells and mRNA expression were measured using EdU assay and quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Immunoblotting and immunofluorescence analysis were conducted to evaluate the… More >

YI HUANG^1,2, CHUNFENG DOU², XUMING HU², HENGMI CUI^2,*

BIOCELL, Vol.46, No.4, pp. 961-967, 2022, DOI:10.32604/biocell.2022.018131

Abstract Metformin is a first-line drug in the fight against type 2 diabetes. In recent years, studies have shown that metformin has some preventive and therapeutic effects on liver cancer, but the effects of metformin on the gene expression of liver cancer cells are not fully known. This study focused on the differences in the gene expression profiles in liver cancer cells treated with or without metformin. A total of 153 differentially expressed genes (DEGs) (FC > 2 and q-values < 0.001) were found, including 77 upregulated genes and 76 downregulated genes. These DEGs are involved in mitogen-activated protein kinase (MAPK),… More >

GASTÓN AMABLE^#, EDUARDO MARTÍNEZ-LEÓN^#, MARÍA E. PICCO, OSVALDO REY

BIOCELL, Vol.46, No.1, pp. 51-59, 2022, DOI:10.32604/biocell.2022.017565

Abstract Colorectal cancer (CRC) is one of the main causes of cancer-related mortality in the developed world despite recent developments in detection and treatment. Several epidemiological studies indicate that metformin, a widely prescribed antidiabetic drug, exerts a protective effect on different cancers including CRC. Furthermore, a recent double-blind placebo-controlled, randomized trial showed that metformin significantly decreased colorectal adenoma recurrence. Studies exploring the mechanism of action of metformin in cells derived from different types of cancers reported many effects including respiratory chain complex 1 inhibition, Akt phosphorylation inhibition, ATP depletion, PKA activation and Wnt signaling inhibition. However, many of these results were… More >

Marziyeh Eftekhari¹, Omid Vahidi^1,*

CMES-Computer Modeling in Engineering & Sciences, Vol.114, No.2, pp. 153-171, 2018, DOI:10.3970/cmes.2018.114.153

Abstract Various drugs are used to maintain normoglycemia in subjects with type 2 diabetes mellitus. The combination of the drugs from different classes in one single tablet may enhance the effectiveness of the anti-diabetic drugs. To investigate the impact of combining drugs on the glucose regulation of subjects with type 2 diabetes, we propose a pharmacokinetic/pharmacodynamics (PK/PD) mathematical modeling approach for a combination of metformin and vildagliptin drugs. In the proposed modeling approach, two separate PK models representing oral administration of metformin and vildagliptin for diabetic subjects are interconnected to a PD model comprising a detailed compartmental physiological model representing the… More >